Competitor Analysis: Tuberculosis Vaccines and Therapeutics

Date: September 1, 2012
Pages: 70
Price:
US$ 516.00
License [?]:
Publisher: La Merie Publishing
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: C2C1095558CEN
Leaflet:

Download PDF Leaflet

Competitor Analysis: Tuberculosis Vaccines and Therapeutics
Product description

The present Competitive Intelligence Report about Tuberculosis Vaccines & Therapeutics provides a competitor evaluation in the field of prophylactic vaccines and therapeutic small molecules and peptides against infection with Mycobacterium tuberculosis as of September 2012. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The WHO estimates that the largest number of new tuberculosis (TB) cases in 2008 occurred in the South-East Asia Region, which accounted for 34% of incident cases globally. However, the estimated incidence rate in sub-Saharan Africa is nearly twice that of the South-East Asia Region with over 350 cases per 100 000 population. An estimated 1.3 million people died from TB in 2008. The highest number of deaths was in the South-East Asia Region, while the highest mortality per capita was in the Africa Region. Until 50 years ago, there were no medicines to cure TB. Now, strains that are resistant to a single drug have been documented in every country surveyed; what is more, strains of TB resistant to all major anti-TB drugs have emerged. Drug-resistant TB is caused by inconsistent or partial treatment. A particularly dangerous form of drug-resistant TB is multidrug-resistant TB (MDR-TB), which is defined as the disease caused by TB bacilli resistant to at least isoniazid and rifampicin, the two most powerful anti-TB drugs.

Private-public partnerships have considerably contributed to establish a tuberculosis vaccine and drug pipeline. So far, there is no approved vaccine for tuberculosis. Now, several vaccines are in clinical development and further in preclinical stages. Small molecule therapeutics are also in clinical and preclinical development and significant research efforts are being undertaken to discover novel small molecule therapeutics with a mechanism of action different from currently used treatments.

The report includes a compilation of currently active projects in development of vaccines and small molecules and peptides targeting Mycobacterium tuberculosis for prophylaxis and treatment of tuberculosis. In addition, the report lists corporate and public R&D pipelines of Tuberculosis Vaccines & Therapeutics. Competitor projects are listed in a tabular format providing information on:
  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.
About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
Index
  • Tuberculosis Vaccines
  • Peptide Therapeutics of Tuberculosis
  • Small Molecule Therapeutics of Tuberculosis
  • Corporate & Public Tuberculosis Vaccines & Therapeutics R&D Pipelines
  • About La Merie

Skip to top


Competitor Analysis: RSV Vaccines and Therapeutics US$ 315.00 Jun, 2012 · 30 pages
Competitor Analysis: CMV Vaccines & Therapeutics US$ 247.00 Aug, 2012 · 23 pages
Competitor Analysis: Anthrax Vaccines & Therapeutics US$ 257.00 Jun, 2013 · 32 pages
Competitor Analysis: HPV Vaccines US$ 170.00 May, 2010 · 18 pages

Ask Your Question

Competitor Analysis: Tuberculosis Vaccines and Therapeutics
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: